Biotechnology - Pixuvri, Pricing

Filter

Current filters:

PixuvriPricing

Popular Filters

UK’s NICE says yes to Cell Thera’s non-Hodgkin’s lymphoma drug Pixuvri

UK’s NICE says yes to Cell Thera’s non-Hodgkin’s lymphoma drug Pixuvri

31-12-2013

US biotech firm Cell Therapeutics’ Pixuvri (pixantrone), a treatment for an aggressive type of cancer…

BiotechnologyCell TherapeuticsEuropeOncologyPixuvriPricingRegulation

Cell Therapeutics reaches price deal with German insurer GKV-SV on Pixuvri

Cell Therapeutics reaches price deal with German insurer GKV-SV on Pixuvri

04-12-2013

US biotech firm Cell Therapeutics has concluded an agreement with the Germany’s National Association…

BiotechnologyCell TherapeuticsOncologyPixuvriPricingRare diseases

Germany's G-BA issues final assessment for Cell Thera's Pixuvri

21-05-2013

USA-based Cell Therapeutics (Nasdaq: CTIC) says that Germany's Federal Joint Committee (G-BA) has issued…

BiotechnologyCell TherapeuticsEuropeOncologyPharmaceuticalPixuvriPricingRegulation

Positive NICE recommendation for Novartis' Lucentis, but not for Cell Thera's Pixuvri

11-04-2013

There was good news for Swiss drug major Novartis (NOVN: VX) this morning, when UK drugs watchdog the…

BiotechnologyCell TherapeuticsEuropeLucentisNovartisOncologyOphthalmicsPharmaceuticalPixuvriPricingRegulation

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top